MX341463B - Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. - Google Patents

Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.

Info

Publication number
MX341463B
MX341463B MX2012013613A MX2012013613A MX341463B MX 341463 B MX341463 B MX 341463B MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 341463 B MX341463 B MX 341463B
Authority
MX
Mexico
Prior art keywords
patients
risk
cll
treatment
antibodies
Prior art date
Application number
MX2012013613A
Other languages
English (en)
Spanish (es)
Other versions
MX2012013613A (es
Inventor
Heider Karl-Heinz
Stilgenbauer Stephan
Zenz Thorsten
Original Assignee
Boehringer Ingelheim Int Gmbh *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341463(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int Gmbh * filed Critical Boehringer Ingelheim Int Gmbh *
Publication of MX2012013613A publication Critical patent/MX2012013613A/es
Publication of MX341463B publication Critical patent/MX341463B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2012013613A 2010-07-16 2011-07-15 Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. MX341463B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (2)

Publication Number Publication Date
MX2012013613A MX2012013613A (es) 2012-12-17
MX341463B true MX341463B (es) 2016-08-22

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013613A MX341463B (es) 2010-07-16 2011-07-15 Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.

Country Status (15)

Country Link
US (3) US20120189618A1 (https=)
EP (2) EP2593479A1 (https=)
JP (2) JP2013538790A (https=)
KR (1) KR20130100918A (https=)
CN (2) CN105749276A (https=)
AU (1) AU2011278227B2 (https=)
BR (1) BR112013001012A2 (https=)
CA (1) CA2799036A1 (https=)
CL (1) CL2013000101A1 (https=)
EA (1) EA025365B1 (https=)
IL (1) IL222775A (https=)
MX (1) MX341463B (https=)
NZ (2) NZ603161A (https=)
PH (1) PH12013500118A1 (https=)
WO (1) WO2012007576A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171287A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
EP3283520B1 (en) 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
AU2018236450A1 (en) * 2017-03-16 2019-10-03 The General Hospital Corporation Chimeric antigen receptors targeting CD37
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
AU2024362226A1 (en) 2023-10-18 2026-03-05 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
HRP20140338T1 (hr) * 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2365003A1 (en) * 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
RU2526156C2 (ru) * 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-иммунотерапевтическая комбинированная терапия и ее применения

Also Published As

Publication number Publication date
US20120189618A1 (en) 2012-07-26
JP2017019800A (ja) 2017-01-26
EA201201660A1 (ru) 2013-07-30
CA2799036A1 (en) 2012-01-19
JP2013538790A (ja) 2013-10-17
IL222775A (en) 2017-10-31
EP3252077A1 (en) 2017-12-06
CN103003309A (zh) 2013-03-27
CL2013000101A1 (es) 2013-12-27
NZ603161A (en) 2015-02-27
CN105749276A (zh) 2016-07-13
WO2012007576A1 (en) 2012-01-19
NZ703225A (en) 2016-11-25
US20130236454A1 (en) 2013-09-12
PH12013500118A1 (en) 2013-03-11
EP2593479A1 (en) 2013-05-22
IL222775A0 (en) 2012-12-31
US20150266967A1 (en) 2015-09-24
EA025365B1 (ru) 2016-12-30
AU2011278227B2 (en) 2017-03-02
KR20130100918A (ko) 2013-09-12
BR112013001012A2 (pt) 2016-05-24
AU2011278227A1 (en) 2012-11-15
MX2012013613A (es) 2012-12-17

Similar Documents

Publication Publication Date Title
MX341463B (es) Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.
Yu et al. LncRNA MEG3 contributes to drug resistance in acute myeloid leukemia by positively regulating ALG9 through sponging miR‐155
Zhong et al. Circ-ITCH sponges miR-214 to promote the osteogenic differentiation in osteoporosis via upregulating YAP1
Zhang et al. miR34a/GOLPH3 axis abrogates urothelial bladder cancer chemoresistance via reduced cancer stemness
Fan et al. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer
Li et al. MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9
Han et al. ROBO3 promotes growth and metastasis of pancreatic carcinoma
Guo et al. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
EP3320093A2 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using slncr isoforms
Liu et al. MiR‐96 regulates bone metabolism by targeting osterix
WO2019083971A1 (en) METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
Zuo et al. Inhibition of HHIP promoter methylation suppresses human gastric cancer cell proliferation and migration
Wang et al. LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway
Wu et al. Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1‐mediated yes‐associated protein inactivation
Song et al. LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p
Yi et al. Epigenetically altered miR-1247 functions as a tumor suppressor in pancreatic cancer
Chen et al. Long non-coding RNA (lncRNA) small nucleolar RNA host gene 15 (SNHG15) alleviates osteoarthritis progression by regulation of extracellular matrix homeostasis
Wang ELF1-activated FOXD3-AS1 promotes the migration, invasion and EMT of osteosarcoma cells via sponging miR-296-5p to upregulate ZCCHC3
Huang et al. Long noncoding RNA SNHG1 promotes human prostate cancer progression by sponging miR-383-5p
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
Cao et al. MiR-1178 promotes the proliferation, G1/S transition, migration and invasion of pancreatic cancer cells by targeting CHIP
WO2021035048A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
Liu et al. MicroRNA-873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β-catenin pathway
Jia et al. Actin‐binding protein Anillin promotes the progression of gastric cancer in vitro and in mice

Legal Events

Date Code Title Description
FG Grant or registration